Protect your skin from the harsh sun rays with La Shield Sunscreen Gel SPF 40. Fortified with SPF 40 and PA+++, it offers superior broad-spectrum protection against both ultraviolet A (UVA) and ultraviolet B (UVB) rays. It doesn’t cause irritation to the skin and is free from preservatives, fragrance, color additives and alcohol. Consisting of an oil-free, non-greasy formulation, this sunscreen spreads easily on the skin giving a matt effect. This sunscreen is non-comedogenic (does not clog pores), water-resistant and dermatologist tested making it suitable for all skin types.
LA Shield Sunscreen Gel SPF 40 provides effective broad-spectrum protection against both Ultraviolet A (UVA) and Ultraviolet B (UVB) rays. Formulated with SPF 40 and PA+++, it protects the skin from harmful effects of UV rays of the sun. It is one of the most trusted sunscreen gel by the dermatologists worldwide and is suitable for all skin types.
Key benefits of Sunscreen SPF 40 Oil-Free Gel La Shield®
SPF 40 and PA +++ provides effective sun protection
Protects skin from UVA and UVB rays
Has oil-free and non-greasy formulation which ensures the matte effect
Does not cause skin irritations or breakouts
It is water-resistant and non-comedogenic
It is free from preservatives and doesn’t cause skin irritations
It has been dermatologically tested and is suitable for all skin types
How to use a Sunscreen Gel SPF 40 La Shield®
Take the sunscreen generously on your palm and apply on the exposed part of the skin
Apply at least 20 minutes before getting under direct sunlight
Re-apply sunscreen after 2 hours or after swimming or sweating
Use it every day: sun emits UV rays round the year
Even on cloudy days: 80% of UV rays can penetrate the clouds
Snow and sand increase the need for sunscreen
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 100 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2012). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis, etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 14 manufacturing facilities in four countries and has six R&D centers spread across India, UK, and Switzerland. It's subsidiary, Glenmark Generics Limited services the requirements of the US and Western Europe generics markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India. Glenmark was founded with a vision to emerge as a leading integrated research-based, a global pharmaceutical company. Over the decades, we have established ourselves as a leading player in the discovery of new molecules both NCEs (New Chemical Entity) and NBEs (New Biological Entity). We have several molecules in various stages of pre-clinical and clinical development and are primarily focused in the areas of Oncology, Respiratory and Dermatology. Our branded generics business has a significant presence in markets across emerging economies including India. The generics business services the requirements of developed markets like US and Western Europe. Our API business sells products in over 80 countries including the US, various countries in the EU, South America and India. With 17 manufacturing facilities and 5 R&D centers dedicated to the goal of enriching lives across the globe we believe that the real force behind our continued successes are dedicated employees from across 50 nationalities, committed to creating 'A new way for a new world'.